中德临床肿瘤学杂志（英文版）
中德臨床腫瘤學雜誌（英文版）
중덕림상종류학잡지（영문판）
THE CHINESE-GERMAN JOURNAL OF CLINICAL ONCOLOGY
2005年
6期
358-360
,共3页
左旋精氨酸%最佳剂量%顺铂%肾毒性
左鏇精氨痠%最佳劑量%順鉑%腎毒性
좌선정안산%최가제량%순박%신독성
L-arginine%optimal dosage%PDD%nephrotoxicity
目的 探讨左旋精氨酸预防大剂量顺铂急性肾毒性的最佳剂量.方法选择128例肿瘤病人,随机分为A、B、C 3组,3组病人顺铂的剂量及用法相同,均为100mg/m2,分两天(第1、2天)给药.3组病人左旋精氨酸的用量分别为每天5g/m2、10g/m2和15g/m2,于化疗的当天在顺铂后应用,每例病人加与不加精氨酸周期的两周期化疗形成自身对照,每例病人化疗前及化疗后24 h均检测尿β2-MG、血尿素氮(BUN)、血肌酐(Cr)及血尿酸,观察3组病人加与不加精氨酸周期化疗前后各观察指标的变化,并比较3组的疗效.结果血BUN、Cr及尿酸无论在加精氨酸周期还是在不加精氨酸周期,化疗前后检测值均无明显变化,该3项指标不宜作为早期急性肾功能损害的检测指标.而A、B、C 3组病人化疗后的尿β2-MG值在加与不加精氨酸周期分别为0.9120±0.6618与1.5167±0.7908(P＜0.05)、0.5404±0.5810与1.4616±0.8120(P＜0.01)及0.4998±0.6210与1.5210±0.7710(P＜0.01),均有明显差别,B组的结果差别极其显著,C组的结果差别也极其显著.A、B、C 3组的显效率及总有效率分别为40.9％及59.1％、68.2％及90.9％、77.5％及97.5％,经x2检验,A、B两组的显效率及总有效率均差别显著,B、G两组的显效率及总有效率均无显著性差别.结论左旋精氨酸有效预防大剂量顺铂急性肾毒性的最佳剂量为每天10g/m2,增加剂量并不增加疗效.
目的 探討左鏇精氨痠預防大劑量順鉑急性腎毒性的最佳劑量.方法選擇128例腫瘤病人,隨機分為A、B、C 3組,3組病人順鉑的劑量及用法相同,均為100mg/m2,分兩天(第1、2天)給藥.3組病人左鏇精氨痠的用量分彆為每天5g/m2、10g/m2和15g/m2,于化療的噹天在順鉑後應用,每例病人加與不加精氨痠週期的兩週期化療形成自身對照,每例病人化療前及化療後24 h均檢測尿β2-MG、血尿素氮(BUN)、血肌酐(Cr)及血尿痠,觀察3組病人加與不加精氨痠週期化療前後各觀察指標的變化,併比較3組的療效.結果血BUN、Cr及尿痠無論在加精氨痠週期還是在不加精氨痠週期,化療前後檢測值均無明顯變化,該3項指標不宜作為早期急性腎功能損害的檢測指標.而A、B、C 3組病人化療後的尿β2-MG值在加與不加精氨痠週期分彆為0.9120±0.6618與1.5167±0.7908(P＜0.05)、0.5404±0.5810與1.4616±0.8120(P＜0.01)及0.4998±0.6210與1.5210±0.7710(P＜0.01),均有明顯差彆,B組的結果差彆極其顯著,C組的結果差彆也極其顯著.A、B、C 3組的顯效率及總有效率分彆為40.9％及59.1％、68.2％及90.9％、77.5％及97.5％,經x2檢驗,A、B兩組的顯效率及總有效率均差彆顯著,B、G兩組的顯效率及總有效率均無顯著性差彆.結論左鏇精氨痠有效預防大劑量順鉑急性腎毒性的最佳劑量為每天10g/m2,增加劑量併不增加療效.
목적 탐토좌선정안산예방대제량순박급성신독성적최가제량.방법선택128례종류병인,수궤분위A、B、C 3조,3조병인순박적제량급용법상동,균위100mg/m2,분량천(제1、2천)급약.3조병인좌선정안산적용량분별위매천5g/m2、10g/m2화15g/m2,우화료적당천재순박후응용,매례병인가여불가정안산주기적량주기화료형성자신대조,매례병인화료전급화료후24 h균검측뇨β2-MG、혈뇨소담(BUN)、혈기항(Cr)급혈뇨산,관찰3조병인가여불가정안산주기화료전후각관찰지표적변화,병비교3조적료효.결과혈BUN、Cr급뇨산무론재가정안산주기환시재불가정안산주기,화료전후검측치균무명현변화,해3항지표불의작위조기급성신공능손해적검측지표.이A、B、C 3조병인화료후적뇨β2-MG치재가여불가정안산주기분별위0.9120±0.6618여1.5167±0.7908(P＜0.05)、0.5404±0.5810여1.4616±0.8120(P＜0.01)급0.4998±0.6210여1.5210±0.7710(P＜0.01),균유명현차별,B조적결과차별겁기현저,C조적결과차별야겁기현저.A、B、C 3조적현효솔급총유효솔분별위40.9％급59.1％、68.2％급90.9％、77.5％급97.5％,경x2검험,A、B량조적현효솔급총유효솔균차별현저,B、G량조적현효솔급총유효솔균무현저성차별.결론좌선정안산유효예방대제량순박급성신독성적최가제량위매천10g/m2,증가제량병불증가료효.
Objective: To explore the optimal dose of L-arginine to prevent acute high-dose (HD)-PDD nephrotoxicity. Methods: 128 cases using PDD with the dosage of 100 mg/m2 within two days (D1, 2)in combination with L-arginine were randomly divided into 3 groups of A, B and C. The dosages of L2 cycles chemotherapy to form self control: 1 cycle combined with L-arginine, while 1 cycle chemotherapy alone. β2-MG in urine, BUN, Cr and uric acid in blood were detected just 24 h before and after using PDD. The changes of each index in the three groups were observed in the presence or absence, and the therapeutic effects were compared among the three groups. Results: There was no significant difference in BUN, Cr and uric acid in blood before and after chemotherapy in the presence or absence, showing these indexes could not be used as markers of early acute nephrotoxicity. Urine β2-MG values in the presence and absence were 0.9120±0.6618 vs 1.5167±0.7908 (P＜0.05), 0.5404±0.5810 vs 1.4616±0.8120 (P＜0.01),0.4998±0.6210 vs 1.5210±0.7710 (P＜0.01) in the groups A, B and C respectively. The excellent effective rate and total effective rate in groups A, B and C were 40.9% and 59.1%, 68.2% and 90.9%, and 77.5% and 97.5%, respectively. There was significant difference in the excellent effective rate and total effective rate between groups A and B, but not between groups B and C. Conclusion: The optimal dose of Laccordingly.
